美国 · SEC FORM 4
Sensei Biotherapeutics, Inc.
SNSE · Nasdaq · CIK 0001829802 · Healthcare
内部人信号
当前没有活跃买入信号
8 qualifying P purchase groups
当前 180 天评分窗口
31 同一窗口内观察到的 Form 4 交易行
4 sales · 4 期权、代扣税、授予、赠与或其他交易行
最近一次合资格买入2026-07-01 · STEPHENSON BRIAN C · $117.5K
为什么没有活跃信号？
买入活动存在
近期买入8 qualifying line group(s)
近期卖出中等
买入信号状态未激活
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
Cluster未计算
买入规模未计算
角色未计算
近期性未计算
确信度未计算
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
买方广度与集中度
合资格买方2
买入集中度95%最大买方： STEPHENSON BRIAN C · $1.1M
聚集买入 · 15天2 insiders峰值活动： 2026-06-22–2026-07-01
Roles in the peak window: Chief Financial Officer, President and CEO. Concentration uses priced qualifying P lines only and does not change the saved score.
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
AprMayJunJulAugSepOct
STEPHENSON BRIAN CChief Financial Officer
●●●●●●●
Parikh Anand KiranPresident and CEO
○○●
Hahn Stephen M.Director
○
Cambrian BioPharma IncTenPercentOwner
▼
Peyer JamesTenPercentOwner,Other
▼
● 买入▼ 卖出○ 其他
—
信号历史
暂无已记录的活跃信号快照
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2026-07-01 · STEPHENSON BRIAN C.
近期 Form 4 活动
31买入
34卖出
6其他 Form 4 交易行
14SEC 申报 · 365天
买入23 qualifying P line(s) · 180 days
卖出4 sale line(s) · 仅供背景
其他4 exercise / withholding / award / gift / other lines
10b5-1／计划交易Not assessed
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
FINRA 报告中没有该股票代码的空头余额。
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-07-01 | STEPHENSON BRIAN C | 买入 (P) | Common Stock | 5,000 | USD 23.50 | USD 117,492 | SEC 申报 ↗ |
| 2026-06-30 | STEPHENSON BRIAN C | 买入 (P) | Common Stock | 7,803 | USD 24.25 | USD 189,240 | SEC 申报 ↗ |
| 2026-06-29 | STEPHENSON BRIAN C | 买入 (P) | Common Stock | 831 | USD 23.34 | USD 19,396 | SEC 申报 ↗ |
| 2026-06-26 | STEPHENSON BRIAN C | 买入 (P) | Common Stock | 6,250 | USD 24.95 | USD 155,908 | SEC 申报 ↗ |
| 2026-06-24 | STEPHENSON BRIAN C | 买入 (P) | Common Stock | 9,391 | USD 26.13 | USD 245,360 | SEC 申报 ↗ |
| 2026-06-23 | STEPHENSON BRIAN C | 买入 (P) | Common Stock | 9,230 | USD 24.36 | USD 224,806 | SEC 申报 ↗ |
| 2026-06-22 | STEPHENSON BRIAN C | 买入 (P) | Common Stock | 8,183 | USD 22.13 | USD 181,115 | SEC 申报 ↗ |
| 2026-06-22 | Parikh Anand Kiran | 买入 (P) | Common Stock | 2,806 | USD 19.76 | USD 55,447 | SEC 申报 ↗ |
| 2026-04-07 | ENGLANDER ISRAEL A; ICS OPPORTUNITIES II LLC; MILLENNIUM GROUP MANAGEMENT LLC; MILLENNIUM MANAGEMENT LLC | 买入 (P) | Common Stock | 1,108 | USD 33.38 | USD 36,985 | SEC 申报 ↗ |
| 2026-04-06 | ENGLANDER ISRAEL A; ICS OPPORTUNITIES II LLC; MILLENNIUM GROUP MANAGEMENT LLC; MILLENNIUM MANAGEMENT LLC | 买入 (P) | Common Stock | 1,104 | USD 31.02 | USD 34,246 | SEC 申报 ↗ |
| 2026-04-02 | ENGLANDER ISRAEL A; ICS OPPORTUNITIES II LLC; MILLENNIUM GROUP MANAGEMENT LLC; MILLENNIUM MANAGEMENT LLC | 买入 (P) | Common Stock | 2,003 | USD 35.01 | USD 70,132 | SEC 申报 ↗ |
| 2026-04-01 | ENGLANDER ISRAEL A; ICS OPPORTUNITIES II LLC; MILLENNIUM GROUP MANAGEMENT LLC; MILLENNIUM MANAGEMENT LLC | 买入 (P) | Common Stock | 6,175 | USD 34.49 | USD 212,999 | SEC 申报 ↗ |
| 2023-09-11 | Celebi John | 买入 (P) | Common Stock | 500 | USD 0.85 | USD 425 | SEC 申报 ↗ |
| 2023-02-23 | Angermayer Christian; Apeiron Investment Group Ltd.; Presight Co-Invest Management, L.L.C.; Presight Sensei Co-Invest Fund, L.P. | 买入 (P) | Common Stock | 2,200 | USD 1.61 | USD 3,542 | SEC 申报 ↗ |
| 2022-03-02 | Peyer James | 买入 (P) | Common Stock | 1,203 | USD 3.20 | USD 3,850 | SEC 申报 ↗ |
Form 4 申报证据
71 transaction lines in the latest 365-day window; 263 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-07-01 | STEPHENSON BRIAN C | 买入 (P) | Common Stock | 5,000 | USD 23.50 | USD 117,492 | SEC 申报 ↗ |
| 2026-06-30 | STEPHENSON BRIAN C | 买入 (P) | Common Stock | 7,803 | USD 24.25 | USD 189,240 | SEC 申报 ↗ |
| 2026-06-29 | STEPHENSON BRIAN C | 买入 (P) | Common Stock | 831 | USD 23.34 | USD 19,396 | SEC 申报 ↗ |
展开近期 Form 4 证据 (30 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-07-01 | STEPHENSON BRIAN C | 买入 (P) | Common Stock | 5,000 | USD 23.50 | USD 117,492 | SEC 申报 ↗ |
| 2026-06-30 | STEPHENSON BRIAN C | 买入 (P) | Common Stock | 7,803 | USD 24.25 | USD 189,240 | SEC 申报 ↗ |
| 2026-06-29 | STEPHENSON BRIAN C | 买入 (P) | Common Stock | 831 | USD 23.34 | USD 19,396 | SEC 申报 ↗ |
| 2026-06-26 | STEPHENSON BRIAN C | 买入 (P) | Common Stock | 6,250 | USD 24.95 | USD 155,908 | SEC 申报 ↗ |
| 2026-06-24 | STEPHENSON BRIAN C | 买入 (P) | Common Stock | 9,391 | USD 26.13 | USD 245,360 | SEC 申报 ↗ |
| 2026-06-23 | STEPHENSON BRIAN C | 买入 (P) | Common Stock | 9,230 | USD 24.36 | USD 224,806 | SEC 申报 ↗ |
| 2026-06-22 | STEPHENSON BRIAN C | 买入 (P) | Common Stock | 8,183 | USD 22.13 | USD 181,115 | SEC 申报 ↗ |
| 2026-06-22 | Parikh Anand Kiran | 买入 (P) | Common Stock | 2,806 | USD 19.76 | USD 55,447 | SEC 申报 ↗ |
| 2026-06-22 | Parikh Anand Kiran | 期权行权／转换 (M) | Common Stock | 53,465 | USD 1.16 | USD 62,019 | SEC 申报 ↗ |
| 2026-06-15 | Parikh Anand Kiran | C (C) | Common Stock | 761,428 | USD — | USD — | SEC 申报 ↗ |
| 2026-06-15 | Hahn Stephen M. | C (C) | Common Stock | 44,763 | USD — | USD — | SEC 申报 ↗ |
| 2026-06-01 | Peyer James | 卖出 (S) | Common Stock | 25,000 | USD 20.02 | USD 500,543 | SEC 申报 ↗ |
| 2026-06-01 | Cambrian BioPharma Inc | 卖出 (S) | Common Stock | 25,000 | USD 20.02 | USD 500,543 | SEC 申报 ↗ |
| 2026-04-07 | ENGLANDER ISRAEL A; ICS OPPORTUNITIES II LLC; MILLENNIUM GROUP MANAGEMENT LLC; MILLENNIUM MANAGEMENT LLC | 卖出 (S) | Common Stock | 8,151 | USD 31.01 | USD 252,752 | SEC 申报 ↗ |
| 2026-04-07 | ENGLANDER ISRAEL A; ICS OPPORTUNITIES II LLC; MILLENNIUM GROUP MANAGEMENT LLC; MILLENNIUM MANAGEMENT LLC | 买入 (P) | Common Stock | 1,108 | USD 33.38 | USD 36,985 | SEC 申报 ↗ |
| 2026-04-06 | ENGLANDER ISRAEL A; ICS OPPORTUNITIES II LLC; MILLENNIUM GROUP MANAGEMENT LLC; MILLENNIUM MANAGEMENT LLC | 卖出 (S) | Common Stock | 1,259 | USD 31.05 | USD 39,096 | SEC 申报 ↗ |
| 2026-04-06 | ENGLANDER ISRAEL A; ICS OPPORTUNITIES II LLC; MILLENNIUM GROUP MANAGEMENT LLC; MILLENNIUM MANAGEMENT LLC | 买入 (P) | Common Stock | 1,104 | USD 31.02 | USD 34,246 | SEC 申报 ↗ |
| 2026-04-02 | ENGLANDER ISRAEL A; ICS OPPORTUNITIES II LLC; MILLENNIUM GROUP MANAGEMENT LLC; MILLENNIUM MANAGEMENT LLC | 卖出 (S) | Common Stock | 7,666 | USD 32.12 | USD 246,219 | SEC 申报 ↗ |
| 2026-04-02 | ENGLANDER ISRAEL A; ICS OPPORTUNITIES II LLC; MILLENNIUM GROUP MANAGEMENT LLC; MILLENNIUM MANAGEMENT LLC | 买入 (P) | Common Stock | 2,003 | USD 35.01 | USD 70,132 | SEC 申报 ↗ |
| 2026-04-01 | ENGLANDER ISRAEL A; ICS OPPORTUNITIES II LLC; MILLENNIUM GROUP MANAGEMENT LLC; MILLENNIUM MANAGEMENT LLC | 卖出 (S) | Common Stock | 1,150 | USD 31.65 | USD 36,397 | SEC 申报 ↗ |
| 2026-04-01 | ENGLANDER ISRAEL A; ICS OPPORTUNITIES II LLC; MILLENNIUM GROUP MANAGEMENT LLC; MILLENNIUM MANAGEMENT LLC | 买入 (P) | Common Stock | 6,175 | USD 34.49 | USD 212,999 | SEC 申报 ↗ |
| 2025-12-09 | Peyer James | 卖出 (S) | Common Stock | 3,507 | USD 7.96 | USD 27,903 | SEC 申报 ↗ |
| 2025-12-09 | Peyer James | 期权行权／转换 (M) | Common Stock | 395 | USD 6.40 | USD 2,528 | SEC 申报 ↗ |
| 2025-12-09 | Cambrian BioPharma Inc | 卖出 (S) | Common Stock | 6,612 | USD 8.25 | USD 54,575 | SEC 申报 ↗ |
| 2025-12-09 | Cambrian BioPharma Inc | 期权行权／转换 (M) | Common Stock | 395 | USD 6.40 | USD 2,528 | SEC 申报 ↗ |
| 2025-12-08 | Peyer James | 卖出 (S) | Common Stock | 3,105 | USD 8.59 | USD 26,672 | SEC 申报 ↗ |
| 2025-12-05 | Peyer James | 卖出 (S) | Common Stock | 16,295 | USD 11.50 | USD 187,390 | SEC 申报 ↗ |
| 2025-12-05 | Cambrian BioPharma Inc | 卖出 (S) | Common Stock | 16,295 | USD 11.50 | USD 187,390 | SEC 申报 ↗ |
| 2025-12-04 | Peyer James | 卖出 (S) | Common Stock | 5,000 | USD 9.06 | USD 45,300 | SEC 申报 ↗ |
| 2025-12-04 | Cambrian BioPharma Inc | 卖出 (S) | Common Stock | 5,000 | USD 9.06 | USD 45,300 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-19 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | SNSE |
| CIK | 0001829802 |
| 行业 | Healthcare |
| 细分行业 | — Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 263 transaction lines from 2021-02-08 to 2026-07-01 164 P purchase lines · 40 S sale lines · 59 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-19. Mapping status is an audit field and does not erase SEC filing evidence.